Provided by Tiger Trade Technology Pte. Ltd.

Alnylam Pharmaceuticals

240.08
+4.071.72%
Post-market: 240.07-0.01000.00%19:58 EDT
Volume:1.58M
Turnover:376.84M
Market Cap:32.03B
PE:42.72
High:240.67
Open:236.56
Low:235.41
Close:236.01
52wk High:495.55
52wk Low:197.81
Shares:133.43M
Float Shares:133.16M
Volume Ratio:0.85
T/O Rate:1.18%
Dividend:- -
Dividend Rate:- -
EPS(TTM):5.62
EPS(LYR):2.33
ROE:96.55%
ROA:12.34%
PB:23.66
PE(LYR):103.04

Loading ...

U.S. Stocks on the MOVE-Mastercard, Starbucks, Meta

Reuters
·
Jul 30

Stock Track | Alnylam Pharmaceuticals Plummets 27.20% in Intraday Trading After Q2 Revenue Miss and Full-Year Guidance Cut

Stock Track
·
Jul 30

Alnylam falls -25.5%

TIPRANKS
·
Jul 30

Movement Alert|Alnylam Pharmaceuticals Falls 20.29% in Regular Trading, Q2 Revenue Misses Estimates as Full-Year Guidance Cut

Market Focus
·
Jul 30

Alnylam Pharmaceuticals' Q2 Adjusted EPS, Revenue Rise; Cuts 2026 Net Product Revenue Guidance; Shares Tumble Pre-Bell

MT Newswires Live
·
Jul 30

Alnylam Pharmaceuticals Shares Down 26% Premarket After Co Trims 2026 Product Sales Forecast

THOMSON REUTERS
·
Jul 30

Alnylam Slips After Trimming 2026 Product Sales Forecast

Reuters
·
Jul 30

Alnylam Q2 Revenue Rises 67% on Increased Demand for Amvuttra

Reuters
·
Jul 30

Alnylam Q2 GAAP Net Income Swings to USD 164.49 Million; Revenue Rises 67% to USD 1.29 Billion vs Q2 FY25

Reuters
·
Jul 30

GUIDANCE: (ALNY) Alnylam Pharmaceuticals Expects 2026 Total Net Product Revenue Range $4.70B - $5.10B

MT Newswires Live
·
Jul 30

Movement Alert|Alnylam Pharmaceuticals Falls 7.45% in Pre-Market Trading, Selling Pressure on Q2 Earnings Release Day

Market Focus
·
Jul 30

Stock Track | Alnylam Pharmaceuticals Plunges 7.45% in Pre-market as Q2 Revenue Misses Estimates

Stock Track
·
Jul 30

Alnylam Pharmaceuticals Q2 Adj. EPS $1.84 Beats $1.55 Estimate, Sales $1.291B Miss $1.323B Estimate

Benzinga Earnings
·
Jul 30

Alnylam Pharmaceuticals Reports Second Quarter 2026 Financial Results and Highlights Recent Period Progress

THOMSON REUTERS
·
Jul 30

Alnylam Pharmaceuticals Q2 Operating Income USD 231.441 Million

THOMSON REUTERS
·
Jul 30

Alnylam Pharmaceuticals Q2 Adjusted EPS USD 1.84 VS. Ibes Estimate USD 1.55

THOMSON REUTERS
·
Jul 30

Earning Preview: Alnylam Pharmaceuticals Q2 revenue is expected to increase by 101%, and institutional views are mostly bullish

Earnings Agent
·
Jul 24

Alnylam Pharmaceuticals is Maintained at Overweight by JP Morgan

Dow Jones
·
Jul 22

Alnylam Pharma (ALNY) Gets a Buy from Oppenheimer

TIPRANKS
·
Jul 22

U.s. Research Roundup-danaher, Gm, Msci

Reuters
·
Jul 22